Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration

American Heart Journal

Volumn 153, Issue 5, 2007, Pages 881-888

  Blanco Colio, Luis Miguel ^a   Martín Ventura, Jose Luis ^a   de Teresa, Eduardo ^b   Farsang, Csaba ^c   Gaw, Allan ^d   Gensini, GianFranco ^e   Leiter, Lawrence A ^f   Langer, Anatoly ^f,g   Martineau, Pierre ^h   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF FLORENCE   (Italy)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g CANADIAN HEART RESEARCH CENTRE   (Canada)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG MECHANISM; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCREENING;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHEMOKINE CCL2; CHOLESTEROL; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME;

EID: 34247166151     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.02.029     Document Type: Article

References (40)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
2. Cines D.B., Pollak E.S., Buck C.A., et al. Endothelial cells in the pathophysiology of vascular disorders. Blood 91 (1998) 3527-3561
3. Krishnaswamy G., Kelley J., Yerra L., et al. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 19 (1999) 91-104
4. Schecter A.D., Rollins B.J., Zhang Y.J., et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 272 (1997) 28568-28573
5. Kitagawa K., Matsumoto M., Sasaki T., et al. Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. Atherosclerosis 160 (2002) 305-310
6. Gu L., Okada Y., Clinton S.K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2 (1998) 275-281
7. Vasan R.S. Biomarkers of cardiovascular disease. Molecular basis and practical considerations. Circulation 113 (2006) 2335-2362
8. Ridker P.M., Hennekens C.H., Roitman-Johnson B., et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 35 (1998) 88-92
9. Hwang S.J., Ballantyne C.M., Sharrett A.R., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96 (1997) 4219-4225
10. de Lemos J.A., Morrow D.A., Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 (2003) 690-695
11. Rohde L.E., Hennekens C.H., and Ridker P.M. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol 19 (1999) 1595-1599
12. Deo R., Khera A., McGuire D.K., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 44 (2004) 1812-1818
13. Martineau P., Gaw A., de Teresa E., et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) Study. Atherosclerosis 191 (2007) 135-146
14. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 284 (2000) 3043-3045
15. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 837-843
16. Blanco-Colio L.M., Tunon J., Martin-Ventura J.L., et al. Inflammatory biomarkers and statins. Drugs Today (Barc) 41 (2005) 171-177
17. Ridker P., Cannon C.P., Morrow D., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
18. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
19. Blanco-Colio L.M., Martin-Ventura J.L., de Teresa E., et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 27 (2007) 168-174
20. Ascer E., Bertolami M.C., Venturinelli M.L., et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177 (2004) 161-166
21. Nawawi H., Osman N.S., Annuar R., et al. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolemia treated with atorvastatin. Atherosclerosis 169 (2003) 283-291
22. Patti G., Chello M., Pasceri V., et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention. J Am Coll Cardiol 48 (2006) 1560-1566
23. Ray K.K., Morrow D.A., Shui A., et al. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). Am J Cardiol 98 (2006) 861-865
24. Seljeflot I., Tonstad S., Hjermann I., et al. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 162 (2002) 179-185
25. Wiklund O., Mattson-Hulten L., Hurt-Camejo E., et al. Effects of simvastatin and atorvastatin on inflammatory markers in plasma. J Intern Med 251 (2002) 338-347
26. Jilma B., Joukhadar C., Derhasching U., et al. Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolemia. Clin Sci (Lond) 104 (2003) 189-193
27. Okopien B., Krysiak R., Haberka M., et al. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipemia. J Cardiovasc Pharmacol 45 (2005) 314-320
28. Kowalski J., Okopien B., Madej A., et al. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia. Eur J Clin Pharmacol 59 (2003) 183-193
29. Bláha V., Andrýs C., Smahelová J., et al. Effect of atorvastatin on soluble CD14, CD40 ligand, sE- and sP-selectin and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover. Pharmacol Res 54 (2006) 421-428
30. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96 (2005) 24F-33F
31. Blanco-Colio L.M., Tunon J., Martin-Ventura J.L., et al. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63 (2003) 12-23
32. Bustos C., Hernandez-Presa M.A., Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32 (1998) 2057-2064
33. De Martin R., Hoeth M., Hofer-Warbinek R., et al. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20 (2000) E83-E88
34. Martin-Ventura J.L., Blanco-Colio L.M., Gomez-Hernandez A., et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 36 (2005) 1796-1800
35. Devaraj S., Davis B., Simon S.I., et al. CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol 291 (2006) H1170-H1176
36. Riesen W.F., Engler H., Risch M., et al. Short-term effects of atorvastatin on C-reactive protein. Eur J Heart 23 (2002) 794-799
37. Blanco-Colio L.M., Martin-Ventura J.L., Sol J.M., et al. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol 43 (2004) 1188-1194
38. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45 (2005) 89-118
39. Ray K.K., and Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndrome. J Am Coll Cardiol 46 (2005) 1425-1433
40. Takeuchi S., Kawashima S., Rikitake Y., et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem Biophys Res Commun 269 (2000) 97-102